Galera Therapeutics regains compliance with Nasdaq MVLS requirement, delisting avoided

Galera Therapeutics, Inc.

Received Nasdaq letter confirming compliance with $50M MVLS requirement for continued listing on Nasdaq Global Market.
Hearing before Nasdaq Hearings Panel on Jan 26, 2023 cancelled.
Company had previously been notified of non-compliance in Dec 2022 and appealed delisting.
Common stock (GRTX) will continue trading on Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.